{
  "name": "follow_up",
  "description": "The collection of data elements related to a specific follow up visit to a donor. A follow up is defined as any point of contact with a patient after diagnosis.",
  "meta": {
    "parent": "donor"
  },
  "fields": [
    {
      "name": "program_id",
      "valueType": "string",
      "description": "Unique identifier of the ARGO program.",
      "meta": {
        "primaryId": true,
        "foreignKey": "sample_registration.program_id"
      },
      "restrictions": {
        "required": true
      }
    },
    {
      "description": "Unique identifier of the donor, assigned by the data provider.",
      "name": "submitter_donor_id",
      "valueType": "string",
      "meta": {
        "primaryId": true,
        "foreignKey": "sample_registration.submitter_donor_id"
      },
      "restrictions": {
        "required": true,
        "regex": "#/regex/submitter_id"
      }
    },
    {
      "description": "Unique identifier for a follow-up event in a donors clincal record, assigned by the data provider.",
      "name": "submitter_follow_up_id",
      "valueType": "string",
      "meta": {
        "primaryId": true
      },
      "restrictions": {
        "required": true,
        "regex": "#/regex/submitter_id"
      }
    },
    {
      "description": "Interval from the primary diagnosis date to the follow up date, in days.",
      "name": "interval_of_followup",
      "valueType": "integer",
      "restrictions": {
        "required": true
      },
      "meta": {
        "core": true,
        "units": "days"
      }
    },
    {
      "description": "Donor's disease status at time of follow-up.",
      "name": "disease_status_at_followup",
      "valueType": "string",
      "restrictions": {
        "required": true,
        "codeList": [
          "Complete remission",
          "Distant progression",
          "Loco-regional progression ",
          "No evidence of disease",
          "Partial remission",
          "Relapse",
          "Stable"
        ]
      },
      "meta": {
        "core": true
      }
    },
    {
      "description": "Donor's relapse type if disease status at followup was progression or relapse.",
      "name": "relapse_type",
      "valueType": "string",
      "restrictions": {
        "codeList": [
          "Distant recurrence/metastasis",
          "Local recurrence",
          "Local recurrence and distant metastasis",
          "Progression (liquid tumours)"
        ]
      },
      "meta": {
        "core": true
      }
    },
    {
      "description": "If the donor was clinically disease free following primary treatment and then relapse or progression (for liquid tumours) occurred afterwards, then this field will indicate the length of disease free interval, in days.",
      "name": "relapse_interval",
      "valueType": "integer",
      "restrictions": {
        "script": "function validate() {\r\n  var result = { valid: true, message: \"depends on disaease_status_at_followup being relapse\" };\r\n  return result;\r\n}\r\n\r\nvalidate();"
      },
      "meta": {
        "core": true,
        "units": "days"
      }
    },
    {
      "description": "Method(s) used to confirm the patient's progression disease status.",
      "name": "method_of_progression_status",
      "valueType": "string",
      "restrictions": {
        "script": "function validate() {\r\n  var result = { valid: true, message: \"depends on disaease_status_at_followup being progression or relapse\" };\r\n  return result;\r\n}\r\n\r\nvalidate();",
        "codeList": [
          "Autopsy",
          "Biomarker in liquid biopsy (e.g. tumor marker in blood or urine)",
          "Biopsy",
          "Blood draw",
          "Bone marrow aspirate",
          "Core biopsy",
          "Cystoscopy",
          "Cytology",
          "Debulking",
          "Diagnostic imaging",
          "Dilation and curettage procedure",
          "Enucleation",
          "Excisional biopsy",
          "Fine needle aspiration",
          "Imaging",
          "Incisional biopsy",
          "Laparoscopy",
          "Laparotomy",
          "Other",
          "Pap Smear",
          "Pathologic review",
          "Physical exam",
          "Surgical resection",
          "Thoracentesis",
          "Ultrasound guided biopsy"
        ]
      },
      "meta": {
        "core": true
      }
    },
    {
      "description": "The anatomic site where disease progression or recurrence occurred.",
      "name": "anatomic_site_progression_or_recurrences",
      "valueType": "string",
      "restrictions": {
        "script": "function validate() {\r\n  var result = { valid: true, message: \"depends on disaease_status_at_followup being progression or relapse\" };\r\n  return result;\r\n}\r\n\r\nvalidate();",
        "codeList": "#/list/anatomic_locations"
      },
      "meta": {
        "core": true
      }
    },
    {
      "description": "Specify the tumour staging system used to stage the cancer at time of retreatment for recurrence or disease progression. This may be represented as rTNM in the medical report.",
      "name": "recurrence_tumour_staging_system",
      "valueType": "string",
      "restrictions": {
        "script": "function validate() {\r\n  var result = { valid: true, message: \"depends on disaease_status_at_followup being progression or relapse\" };\r\n  return result;\r\n}\r\n\r\nvalidate();",
        "codeList": [
          "Binet",
          "Rai",
          "FIGO",
          "Ann Arbor",
          "Murphy",
          "Lugano",
          "AJCC 8th Edition",
          "AJCC 7th Edition",
          "AJCC 6th Edition",
          "AJCC 5th Edition",
          "AJCC 4th Edition",
          "AJCC 3rd Edition",
          "AJCC 2nd Edition",
          "AJCC 1st Edition"
        ]
      },
      "meta": {
        "core": true
      }
    },
    {
      "name": "recurrence_t_category",
      "description": "The code to represent the extent of the primary tumour (T) based on evidence obtained from clinical assessment parameters determined after treatment for patients receiving systemic and/or radiation therapy alone or as a component of their initial treatment, or as neoadjuvant therapy before planned surgery, according to criteria based on multiple editions of the AJCC's Cancer Staging Manual.",
      "valueType": "string",
      "restrictions": {
        "script": "function validate() {\r\n  var result = { valid: true, message: \"only required if on recurrence_tumour_staging_system is AJCC\" };\r\n  return result;\r\n}\r\n\r\nvalidate();"
      },
      "meta": {
        "core": true
      }
    },
    {
      "name": "recurrence_n_category",
      "description": "The code to represent the stage of cancer defined by which is the extent of the regional lymph node (N) involvement for the cancer based on evidence obtained from clinical assessment parameters determined determined at the time of retreatment for a recurrence or disease progression, according to criteria based on multiple editions of the AJCC's Cancer Staging Manual.",
      "valueType": "string",
      "restrictions": {
        "script": "function validate() {\r\n  var result = { valid: true, message: \"only required if on recurrence_tumour_staging_system is AJCC\" };\r\n  return result;\r\n}\r\n\r\nvalidate();"
      },
      "meta": {
        "core": true
      }
    },
    {
      "name": "recurrence_m_category",
      "description": "The code to represent the stage of cancer defined bythe extent of the distant metastasis (M) for the cancer based on evidence obtained from clinical assessment parameters determined determined at the time of retreatment for a recurrence or disease progression, according to criteria based on multiple editions of the AJCC's Cancer Staging Manual.",
      "valueType": "string",
      "restrictions": {
        "script": "function validate() {\r\n  var result = { valid: true, message: \"only required if on recurrence_tumour_staging_system is AJCC\" };\r\n  return result;\r\n}\r\n\r\nvalidate();"
      },
      "meta": {
        "core": true
      }
    },
    {
      "name": "recurrence_stage_group",
      "description": "The code to represent the stage group of the tumour, as assigned by the reporting recurrence_tumour_staging_system, that indicates the overall prognostic tumour stage (ie. Stage I, Stage II, Stage III etc.) after treatment for patients receiving systemic and/or radiation therapy alone or as a component of their initial treatment, or as neoadjuvant therapy before planned surgery.",
      "valueType": "string",
      "restrictions": {
        "script": "function validate() {\r\n  var result = { valid: true, message: \"only required if on recurrence_tumour_staging_system is AJCC\" };\r\n  return result;\r\n}\r\n\r\nvalidate();"
      },
      "meta": {
        "core": true
      }
    },
    {
      "description": "Specify the tumour staging system used to stage the cancer after treatment for patients receiving systemic and/or radiation therapy alone or as a component of their initial treatment, or as neoadjuvant therapy before planned surgery. This may be represented as ypTNM or ycTNM in the medical report.",
      "name": "posttherapy_tumour_staging_system",
      "valueType": "string",
      "restrictions": {
        "script": "function validate() {\r\n  var result = { valid: true, message: \"depends on disaease_status_at_followup being progression or relapse\" };\r\n  return result;\r\n}\r\n\r\nvalidate();",
        "codeList": [
          "Binet",
          "Rai",
          "FIGO",
          "Ann Arbor",
          "Murphy",
          "Lugano",
          "AJCC 8th Edition",
          "AJCC 7th Edition",
          "AJCC 6th Edition",
          "AJCC 5th Edition",
          "AJCC 4th Edition",
          "AJCC 3rd Edition",
          "AJCC 2nd Edition",
          "AJCC 1st Edition"
        ]
      }
    },
    {
      "name": "posttherapy_t_category",
      "description": "The code to represent the extent of the primary tumour (T) based on evidence obtained from clinical assessment parameters determined after treatment for patients receiving systemic and/or radiation therapy alone or as a component of their initial treatment, or as neoadjuvant therapy before planned surgery, according to criteria based on multiple editions of the AJCC's Cancer Staging Manual.",
      "valueType": "string",
      "restrictions": {
        "script": "function validate() {\r\n  var result = { valid: true, message: \"only required if on post_therapy_tumour_staging_system is AJCC\" };\r\n  return result;\r\n}\r\n\r\nvalidate();"
      }
    },
    {
      "name": "posttherapy_n_category",
      "description": "The code to represent the stage of cancer defined by which is the extent of the regional lymph node (N) involvement for the cancer based on evidence obtained from clinical assessment parameters determined determined after treatment for patients receiving systemic and/or radiation therapy alone or as a component of their initial treatment, or as neoadjuvant therapy before planned surgery, according to criteria based on multiple editions of the AJCC's Cancer Staging Manual.",
      "valueType": "string",
      "restrictions": {
        "script": "function validate() {\r\n  var result = { valid: true, message: \"only required if on post_therapy_tumour_staging_system is AJCC\" };\r\n  return result;\r\n}\r\n\r\nvalidate();"
      }
    },
    {
      "name": "posttherapy_m_category",
      "description": "The code to represent the stage of cancer defined bythe extent of the distant metastasis (M) for the cancer based on evidence obtained from clinical assessment parameters determined determined after treatment for patients receiving systemic and/or radiation therapy alone or as a component of their initial treatment, or as neoadjuvant therapy before planned surgery, according to criteria based on multiple editions of the AJCC's Cancer Staging Manual.",
      "valueType": "string",
      "restrictions": {
        "script": "function validate() {\r\n  var result = { valid: true, message: \"only required if on post_therapy_tumour_staging_system is AJCC\" };\r\n  return result;\r\n}\r\n\r\nvalidate();"
      }
    },
    {
      "name": "posttherapy_stage_group",
      "description": "The code to represent the stage group of the tumour, as assigned by the reporting posttherapy_tumour_staging_system, that indicates the overall prognostic tumour stage (ie. Stage I, Stage II, Stage III etc.) after treatment for patients receiving systemic and/or radiation therapy alone or as a component of their initial treatment, or as neoadjuvant therapy before planned surgery.",
      "valueType": "string",
      "restrictions": {
        "script": "function validate() {\r\n  var result = { valid: true, message: \"only required if on post_therapy_tumour_staging_system is AJCC\" };\r\n  return result;\r\n}\r\n\r\nvalidate();"
      }
    }
  ]
}
